New Delhi: Biophore India Pharmaceuticals on Friday announced that it has applied for DCGI emergency use approval of Aviptadil Inhalation for marketing in India for the treatment of moderate to severe cases of Covid-19.
Biophore has successfully developed Aviptadil, a synthetic form of Vasoactive Intestinal Peptide (VIP) for rapid Covid-19 clinical recovery and is backward integrated with in-house API, stated the release by the company, adding that it will start commercial production after receiving the stipulated approval from DCGI.
The company has submitted results from multiple trials of Aviptadil for observing its role in recovery in Covid-19 patients with respiratory failure to the DCGI for review.
Dr. Jagadeesh Babu Rangisetty, CEO at Biophore, said, “Biophore has developed this highly complex peptide in a very short period of time, primarily due to the extensive focus of the company in prioritizing Covid related products over the last one year. Aviptadil is a very promising treatment option for Covid, especially in severe hospitalized cases where trials have shown a high recovery percentage and we hope to be able to quickly make it available through this approval.”
“While we are optimistic that the pandemic will end soon, we have to be prepared for the exigencies. We need to keep evaluating and adding newer products against this virus to ensure better preparedness by having more options for the treating physicians and thus avoiding shortages. Our aim is also to make the cost of treatment affordable, especially for hospitalized patients,” he added.